for your role

Configure the controls. Don't code them. Don't re-validate them every time the FDA expands Part 11.

The Validation Lead at a regulated life-sciences operator carries the cost of every FDA Part 11 expansion. Each new sub-clause — AI-assisted decision support, remote monitoring, cloud-deployment witnessing, e-signature scope expansion — historically requires a vendor project to validate. Months of work; six-figure cost; recurring with each FDA Part 11 update. The validated-state drift between updates is itself a finding.

Talk to a Validation solutions engineer · Read the FDA 21 CFR Part 11 overlay

Image: Part 11 control matrix with rows for each Part 11 sub-clause and columns for "configurable / coded"; TeamSync rows mostly green (configurable) with Merkle audit anchors; legacy systems rows mostly amber/red (coded + custom).

"Every new Part 11 expansion costs me a vendor project to validate."

"Every new Part 11 expansion costs me a vendor project to validate. The cost is unsustainable." — Validation Lead, life-sciences mid-market

3 failure modes recur:

Each legacy GMP system has its own Part 11 controls implemented as custom code. Vendor change → re-validation.
Sub-clause expansions (AI-decision-support; cloud-witnessing) trigger custom-control work in every system. Multi-vendor multiplier.
The validated baseline drifts as systems patch, upgrade, or integrate. Validated-state assertions become inferences.

What TeamSync gives the Validation Lead.

1. Part 11 controls as configurable, not coded.

The configurable controls in TeamSync — record retention, audit trail, e-signature flows, access controls, copy/print restrictions — map to Part 11 Sections 11.10, 11.30, 11.50, 11.70, 11.100. Configuration changes do not require code re-validation; the validation pack covers the configuration surface.

2. Validated baseline deployed; audit-anchored.

The TeamSync validation pack provides the IQ/OQ/PQ documentation, the validation-test scripts, the user-acceptance evidence — all baseline-deployed. The customer's incremental validation effort is per their specific configuration, not a full ground-up validation.

3. Validated-state drift detected automatically.

The audit ledger anchors every change to the configured controls. Any drift from the validated baseline surfaces as an audit-ledger event flagged for the validation team.

4. Part 11 expansions absorbed via configuration.

When the FDA expands Part 11 (recent: AI-assisted decision support, remote monitoring, cloud-deployment witnessing), TeamSync's configurable surface absorbs the change. The Validation Lead applies the configuration; the validation pack is delta-validated; production goes live without a multi-month vendor project.

Compliance frameworks served.

Framework	Coverage
FDA 21 CFR Part 11 Sections 11.10, 11.30, 11.50, 11.70, 11.100	Configurable controls + validated baseline
EU GMP Annex 11	Equivalent EU computerised-system requirements
GAMP 5	Risk-based validation approach
ICH Q9 (Quality Risk Management)	Risk-based control configuration
HIPAA, SOC 2, ISO 27001	Cross-vertical

CTAs.

If you are…	Do this
Validation Lead	Talk to a solutions engineer
CQO sponsoring the validation programme	Read the CQO page
Regulatory Affairs Lead preparing for Part 11 expansion	Read the FDA Part 11 overlay

Intelligent Repository, Electronic & Digital Signatures, Business Rules Engine, Tamper-evident audit ledger

FDA 21 CFR Part 11, HIPAA, SOC 2